Grant: Doctoral Research Award - Priority Announcement: Patient-Oriented Research
University of Calgary
$70,000.00
VITAH Trial - Vitamin D supplementation and cardiac autonomic tone in hemodialysis: A blinded, randomized-controlled trial
EF 2012-13
Résumé
Chronic kidney disease affects 13% of the Canadian population, a portion of the public which has now grown to surpass the number of those suffering from diabetes. Cardiovascular disease is the leading cause of death in chronic kidney disease patients in Canada and worldwide, despite treatment of traditional risk factors. In humans, heart rate is controlled by stimulatory and inhibitory input from the cardiac autonomic nervous system. Specialized computer software can quantify the level of activity from these two opposing limbs by assessing the beat-to-beat changes in heart rate, termed "heart rate variability," from a typical heart monitor reading. Abnormal heart rate variability, and thus abnormal autonomic nervous system activity, has been identified as a predictor of both cardiovascular and sudden death.
The prevalence of vitamin D deficiency in those suffering from kidney disease is also extremely high. Many studies have shown that poor vitamin D status (either insufficiency or deficiency), kidney dysfunction, and increased risk of cardiovascular disease are associated with one another. Thus, improving low vitamin D levels with supplementation may lead to an improvement in heart rate variability in this population.
For the first time, this blinded, randomized-controlled trial will investigate the impact of vitamin D supplementation on heart rate variability in a population of high-risk hemodialysis patients. Based on our laboratory's previous findings in humans who are healthy and whom have early stages of kidney dysfunction, we hypothesize that oral vitamin D supplementation to will lead to an improvement in heart rate variability parameters, thus indicating an improvement in cardiovascular risk, specifically during the high-risk period following the two day dialysis-free period. These findings would support the role of vitamin D supplementation in reducing the burden of cardiovascular disease and death within the chronic kidney disease population.
Programme
Doctoral Research Award - Priority Announcement: Patient-Oriented Research
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
272666
Name
Mann Michelle C
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Nutrition, Metabolism and Diabetes
Theme2
Clinical
Prcname2
Doctoral Research Awards - A
Projecttitle
VITAH Trial - Vitamin D supplementation and cardiac autonomic tone in hemodialysis: A blinded, randomized-controlled trial
Programtype2
Studentship Programs
Orgnameinp2
University of Calgary
Cihramount2
$70,000
Cihrequipment2
$0
Programname2
Doctoral Research Award - Priority Announcement: Patient-Oriented Research
Keyworddelim
Autonomic Nervous System; Chronic Kidney Disease; Hemodialysis; Sudden Cardiac Death; Vitamin D
Abstract
Chronic kidney disease affects 13% of the Canadian population, a portion of the public which has now grown to surpass the number of those suffering from diabetes. Cardiovascular disease is the leading cause of death in chronic kidney disease patients in Canada and worldwide, despite treatment of traditional risk factors. In humans, heart rate is controlled by stimulatory and inhibitory input from the cardiac autonomic nervous system. Specialized computer software can quantify the level of activity from these two opposing limbs by assessing the beat-to-beat changes in heart rate, termed "heart rate variability," from a typical heart monitor reading. Abnormal heart rate variability, and thus abnormal autonomic nervous system activity, has been identified as a predictor of both cardiovascular and sudden death.
The prevalence of vitamin D deficiency in those suffering from kidney disease is also extremely high. Many studies have shown that poor vitamin D status (either insufficiency or deficiency), kidney dysfunction, and increased risk of cardiovascular disease are associated with one another. Thus, improving low vitamin D levels with supplementation may lead to an improvement in heart rate variability in this population.
For the first time, this blinded, randomized-controlled trial will investigate the impact of vitamin D supplementation on heart rate variability in a population of high-risk hemodialysis patients. Based on our laboratory's previous findings in humans who are healthy and whom have early stages of kidney dysfunction, we hypothesize that oral vitamin D supplementation to will lead to an improvement in heart rate variability parameters, thus indicating an improvement in cardiovascular risk, specifically during the high-risk period following the two day dialysis-free period. These findings would support the role of vitamin D supplementation in reducing the burden of cardiovascular disease and death within the chronic kidney disease population.
Competitiondate
201210
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Mann, Michelle C
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $70,000~ $0~